Ophthotech (OPHT) Mega Million Deal with Novartis (NVS)

New Post Public Reply Private Reply Replies (0) Message Board
riddock57
Ophthotech Corporation (OPHT) said that it has entered into an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals (NVS) focused on the treatment of wet age-related macular degeneration (AMD).

Under the agreement, the company grants Novartis exclusive rights to commercialize OPHT’s Fovista(R), in markets outside the United States while OPHT retains sole rights to commercialize Fovista(R) in the U.S.

Potential payments to OPHT under the agreement could total over $1 billion in upfront and milestone payments, not including future royalties. OPHT could receive immediate payment and near-term milestones totaling up to $330 million, including an upfront fee of $200 million and Fovista(R) Phase 3 enrollment-based milestones of up to $130 million. OPHT is entitled to receive royalties on ex-US Fovista(R) sales.

OPHT’s Fovista(R) is the most advanced anti-PDGF agent in development for the treatment of wet AMD and, if approved, is expected to be first to market in this class of therapies for wet AMD.

OPHT is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye, with a focus on developing innovative therapies for age-related macular degeneration (AMD).

More about Ophthotech Corporation (OPHT) at www.ophthotech.com

**

Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network (CRWE-PR), a social networking service which business model is based on selling advertising to local businesses.

The CRWE Network has reached the 571st community website in the U.S., associated with 2137 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 10 provinces in Canada

The CRWE-PR Finance website (www.finance.crwe-pr.com), in development stage and currently online, allows CRWE the instant distribution of information to the entire CRWE Network community of websites in the U.S. and Canada

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com or the CRWE Network at www.CRWE-PR.com

**

Oncolytics Biotech Inc. (ONCY) reported that an abstract detailing early data from translational study looking at the intravenous administration of its REOLYSIN(R) to patients with primary or metastatic brain tumors will be presented at the at the American Society of Clinical Oncology Annual Meeting being held May 30 – June 3, 2014 in Chicago, Illinois.

Based on the findings, the researchers concluded they have shown for the first time that an oncolytic virus, wild-type reovirus, infects and replicates in brain tumors following intravenous administration. It is anticipated this trial could pave the way for phase I/II trials and combination studies using wild-type reovirus in patients with high grade gliomas and brain metastases.

Treatment options for patients with brain cancer often include invasive surgery and local administration of therapeutic agents.

According to ONCY, with this early data suggesting that reovirus can cross the blood brain barrier, it may provide physicians with another, less invasive option in the treatment of both primary brain cancer and metastatic disease associated with other cancer types, which is estimated to occur in about one quarter of all cancer cases where it spreads through the body

The abstract, titled "Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients," contends that intravenous delivery to brain tumors would be easier, cheaper and more acceptable to patients than intralesional administration. To date, no oncolytic virus has been shown to infect brain tumors following intravenous delivery.

ONCY is focused on the development of oncolytic viruses as potential cancer therapeutics.

More about Oncolytics Biotech Inc. (ONCY) at www.oncolyticsbiotech.com.

**

Keep a close eye on Tarena International, Inc. (TEDU). The company reported strong performance on its first quarterly financial results as a public company.

For the first quarter 2014, TEDU posted net revenues of $24.3 million, a 60.7% increase year over year, gross profit of $15.8 million, a 72.6% increase compared to the same period the prior year, and net income of $1.0 million, representing a 1998.3% increase compared to the first quarter 2013

TEDU expects total net revenues for the second quarter of 2014 to be between $30.5 million and $31.5 million, representing an increase of 47% to 51% on a year-over-year basis.

TEDU is a leading provider of professional education services in China.

More about Tarena International, Inc. (TEDU) at ir.tarena.com.cn

**

CRWE-PR Finance: www.finance.crwe-pr.com/2014/05/20/ophthotech-opht-mega-million-deal-with-novartis-nvs-oncolytics-biotech-oncy-brain-cancer-trial-positive-data-tarena-international-tedu-solid-results

Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer

Novartis Ag (NVS) Stock Research Links

NVS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MedStar's Same-Day Test Puts Stroke Drugs on Notice

Updated Category News Views 40

A five-hour lab result can matter more than another glossy precision-medicine slogan. MedStar Health says it is using same-day genetic testing for patients with ischemic stroke, giving clinicians information before discharge that previously often arrived more than a week later. That is a practical change, not science-fiction wallpaper: a treatment decision gets made while...

Continue Reading
Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 0

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
Century Lithium Clears a Crucial Nevada Permit Gate

Updated Category News Views 65

Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 138

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 143

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 85

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Accredited Debt Relief Earns Personalized Honor in 2026

Updated Category News Views 45

A High Score Is Useful, Not a Free Pass Debt relief rankings can get awfully shiny when a company has a good week, but this one has some actual detail behind it. USA Today named Accredited Debt Relief its best provider for personalized debt relief in its 2026 review, handing the company a 94 out of 100. The ranking was published November 11 and updated November 12, and...

Continue Reading
Qiandaohu Whisky Film Puts Craft Before Market Hype

Updated Category News Views 59

Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...

Continue Reading

Top 5 Most Recently Viewed Articles

A&K Robotics Strengthens Leadership with Melonee Wise's Expertise

Updated Category News Views 289

Leadership Expansion at A&K Robotics A&K Robotics, a frontrunner in the autonomous micromobility sector, is excited to welcome Melonee Wise to its Board of Advisors. With over twenty years of rich experience in developing robotic technologies, Wise is poised to offer invaluable insights as the company continues to grow its influence worldwide. Advancing Mobility Through...

Continue Reading
Lavior Welcomes Ryan Shilling as New VP of Sales for U.S.

Updated Category News Views 147

Lavior Welcomes Ryan Shilling as New VP of Sales for U.S. Healthcare Expertise to Drive Growth and Patient-Centered Innovation Lavior, an innovator in advanced healing solutions, proudly announces the appointment of Ryan Shilling as Vice President of Sales for the U.S. market. With over 15 years of leadership experience in various healthcare sectors, Shilling is set to...

Continue Reading
Tesla's Cybertruck Delivery Plans Set to Launch in Canada

Updated Category News Views 372

Tesla Gears Up for Cybertruck Deliveries in Canada Tesla Inc. (NASDAQ: TSLA) is approaching an exciting milestone as it plans to start delivering its much-anticipated Cybertruck in Canada shortly. Recent updates on social media suggest that the event could happen as early as next week, thrilling prospective owners. Exciting Customer Announcements On social media platform...

Continue Reading
Borregaard ASA Announces Ex-Dividend Trading Notification

Updated Category News Views 191

Borregaard ASA Ex-Dividend Trading Insights Today marks the beginning of a new trading phase for Borregaard ASA as its shares are now officially traded ex-dividend at NOK 4.25 per share. This means that investors purchasing shares at this point will not receive the forthcoming dividend, which can influence buying decisions in the market. Understanding Ex-Dividend Dates...

Continue Reading
Key Legal Notice for Charter Communications' Shareholders

Updated Category News Views 189

Current Updates on Charter Communications, Inc. Charter Communications, Inc. (NASDAQ: CHTR) has been generating significant attention as it faces an ongoing class action lawsuit regarding securities fraud. This legal proceeding serves to remind shareholders of their rights and the timelines that are critical for participation. With the stakes involved, it is vital for...

Continue Reading